遼寧成大(600739.SH):子公司擬將其本溪人用疫苗業務的相關資產及負債劃轉至本溪子公司
格隆匯2月22日丨遼寧成大(600739.SH)公佈,公司於2022年2月22日召開第十屆董事會第八次(臨時)會議,審議通過了《關於公司控股子公司遼寧成大生物股份有限公司將其本溪人用疫苗基地相關資產、負債及人員劃轉至其全資子公司的議案》,同意公司控股子公司遼寧成大生物股份有限公司(簡稱“成大生物”)以2022年1月31日為基準日將其本溪人用疫苗業務相關的資產及負債按照賬面淨值劃轉至其全資子公司成大生物(本溪)有限公司(簡稱“本溪子公司”)。
為保障成大生物募投項目的順利實施,成大生物擬將募投項目“遼寧成大生物股份有限公司本溪分公司人用疫苗一期工程建設項目”的實施主體由“成大生物本溪分公司”變更為“本溪子公司”,該募投項目相關的實施地點、實施內容、實施方案等均保持不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.